Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 5

Clinical efficacy of farcosolvin syrup (ambroxol–theophylline–guaiphenesin mixture) in the treatment of acute exacerbation of chronic bronchitis

Authors Yakoot M, Salem A, Omar A

Published 20 July 2010 Volume 2010:5 Pages 251—256

DOI https://doi.org/10.2147/COPD.S10981

Review by Single-blind

Peer reviewer comments 2

Mostafa Yakoot1, Amel Salem2, Abdel-Mohsen Omar3
1Green Clinics and Research Center, Alexandria, Egypt; 2Al-Mabarah Hospital, 3Faculty of Pharmacy, Alexandria University, Alexandria, Egypt

Background: Acute exacerbations of chronic bronchitis (AECB) are defined as recurrent attacks of worsening bronchial inflammation that are marked by an increase in the volume of daily sputum produced, a change in color of the expectorated sputum, and worsening dyspnea. Farcosolvin® (Pharco Pharmaceuticals, Alexandria, Egypt) is a mixture of ambroxol (15 mg); theophylline (50 mg); and guaiphenesin (30 mg), per 5 mL syrup.

Objective: To test the clinical efficacy of Farcosolvin in the treatment of AECB in a randomized, single-blinded, controlled study design.

Patients and methods: One hundred patients with AECB were randomized to either Farcosolvin or guaiphenesin treatment groups, in addition to the standard medical treatment for their cases. Baseline clinical symptomatolgy of breathlessness, cough, and sputum severity scoring were compared before and after 3 and 7 days of treatment in both groups and the differences compared between groups. Changes in perceived improvement were also compared between groups using the Clinical Global Impression of Improvement or Change Scale (CGIC).

Results: There were statistically significant improvements in breathlessness and cough scores in both groups (pretreatment versus posttreatment at day 3 and at day 7; P < 0.05). There were highly statistically significant differences between groups in improvement in ­breathlessness and cough scores, after 3 and 7 days treatment, in favor of the Farcosolvin ­treatment group (P < 0.001). Out of 50 patients, 48 (96%) in the Farcosolvin-treated group rated their ­improvement on the CGIC scale as “much” and “very much” improved, while only 41 patients (82%) reported such a degree of improvement in the control group. The difference was statistically significant (P < 0.05).

Conclusion: We concluded from our study that Farcosolvin syrup might be safe and effective in improving symptoms in cases of acute exacerbation of chronic bronchitis.

Keywords: acute exacerbation of chronic bronchitis, ambroxol, theophylline

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other articles by this author:

Effect of a topical copper indomethacin gel on inflammatory parameters in a rat model of osteoarthritis

Yassin NZ, El-Shenawy SM, Abdel-Rahman RF, Yakoot M, Hassan M, Helmy S

Drug Design, Development and Therapy 2015, 9:1491-1498

Published Date: 12 March 2015

Readers of this article also read:

Enhanced local bioavailability of single or compound drugs delivery to the inner ear through application of PLGA nanoparticles via round window administration

Cai H, Wen X, Wen L, Tirelli N, Zhang X, Zhang Y, Su H, Yang F, Chen G

International Journal of Nanomedicine 2014, 9:5591-5601

Published Date: 1 December 2014

Covalent IR820-PEG-diamine nanoconjugates for theranostic applications in cancer

Fernandez-Fernandez A, Manchanda R, Carvajal DA, Lei T, Srinivasan S, McGoron AJ

International Journal of Nanomedicine 2014, 9:4631-4648

Published Date: 6 October 2014

Amorphous silica nanoparticles impair vascular homeostasis and induce systemic inflammation

Nemmar A, Albarwani S, Beegam S, Yuvaraju P, Yasin J, Attoub S, Ali BH

International Journal of Nanomedicine 2014, 9:2779-2789

Published Date: 2 June 2014

Efficacy and safety of tiotropium Respimat® SMI in COPD in two 1-year randomized studies

Eric Bateman, Dave Singh, David Smith, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:197-208

Published Date: 9 June 2010